[DOI] [PubMed] [Google Scholar] 102.Jang H-J, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim B-J, Zhou J, Kim HH, Xu X, Chan SL, Juhaszova M, Bernier M, Mosinger B, Margolskee RF, Egan JM
Evidence Summary Current evidence supports the following conclusions: GLP-1 drugs reduce caloric intake Reduced intake may reduce micronutrient consumption Delayed gastric emptying does not equal malabsorption Rapid weight loss may increase lean mass vulnerability Long-term micronutrient outcome data remain limited There is mechanistic plausibility for nutritional risk in certain populations, but no strong evidence of universal depletion across all patients
GLP-1 medications are among the most effective, clinically proven treatments for sustainable weight loss and WellMedr was built to help patients get the most out of them through continuous support, medical guidance, and modern telehealth
10.1111/dom.12539 2 AhrnB.Leguizamo DimasA.MiossecP.SaubaduS.AronsonR